title: Development of vizantin, a safe immunostimulant, based on the structure-activity relationship of trehalose-6,6'-dicorynomycolate.
abstract: Vizantin, 6,6'-bis-O-(3-nonyldodecanoyl)-α,α'-trehalose, was developed as a safe immunostimulator on the basis of a structure-activity relationship (SAR) study with trehalose 6,6'-dicorynomycolate (TDCM). It was possible to synthesize vizantin on a large scale more easily than in the case of TDCM, and the compound exhibited more potent prophylactic effect on experimental lung metastasis of B16-F0 melanoma cells. Because vizantin stimulated human macrophages, it is a promising candidate for clinical application.
authors.affiliation: Faculty of Pharmaceutical Sciences, Tokushima Bunri University, Yamashiro-cho, Tokushima 770-8514, Japan. hirofumi@ph.bunri-u.ac.jp
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Yamamoto
authors.forename: Masataka
authors.initials: M
authors.lastname: Oda
authors.forename: Mayo
authors.initials: M
authors.lastname: Nakano
authors.forename: Naoyuki
authors.initials: N
authors.lastname: Watanabe
authors.forename: Kenta
authors.initials: K
authors.lastname: Yabiku
authors.forename: Masahiro
authors.initials: M
authors.lastname: Shibutani
authors.forename: Masahisa
authors.initials: M
authors.lastname: Inoue
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Imagawa
authors.forename: Masahiro
authors.initials: M
authors.lastname: Nagahama
authors.forename: Seiichiro
authors.initials: S
authors.lastname: Himeno
authors.forename: Kojun
authors.initials: K
authors.lastname: Setsu
authors.forename: Jun
authors.initials: J
authors.lastname: Sakurai
authors.forename: Mugio
authors.initials: M
authors.lastname: Nishizawa
mesh_terms: D000276:Adjuvants, Immunologic / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D045744:Cell Line, Tumor; D003311:Cord Factors / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D006017:Glycolipids / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D008175:Lung Neoplasms / Q000517:prevention & control / Q000556:secondary; D008264:Macrophages / Q000187:drug effects / Q000276:immunology; D008546:Melanoma, Experimental / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D010587:Phagocytosis / Q000187:drug effects; D013237:Stereoisomerism; D013329:Structure-Activity Relationship; D014199:Trehalose / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D023041:Xenograft Model Antitumor Assays
chemical_list: C579729:6,6'-bis-O-(3-nonyldodecanoyl)-alpha,alpha'-trehalose; D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D003311:Cord Factors; D006017:Glycolipids; C043399:6,6'-dicorynomycolyl trehalose; D014199:Trehalose